The dulaglutide data were revealed today at the annual American Diabetes Association meeting. Dulaglutide could restore some pride in Lilly's much-maligned R&D engine.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

对于 2 型糖尿病（T2D）血糖控制不佳的患者，提升 Dulaglutide（胰高血糖素样肽 - 1 受体激动剂，GLP - 1）剂量不如换用 Tirzepatide。研究发现，换用并加量 Tirzepatide 者 40 周后 21% 的人糖化血红蛋白 A1c（HbA1c）达标，且减重效果更好，安全性相似。此研究为 T2D 治疗提供新方向。

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

2020年09月27日讯 / 生物谷 BIOON/ -- 礼来 （Eli Lilly）近日宣布，加拿大卫生部（Health Canada）已批准降糖药Trulicity（dulaglutide，度拉鲁肽），该药是一种 ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

实验证实dulaglutide和romiplostim在皮下组织及淋巴液中发生蛋白区域降解，而abatacept和etanercept保持稳定，为临床给药方案优化提供新依据。 在生物制药领域，Fc融合蛋白因其通过IgG的Fc结构域延长半衰期的特性，已成为治疗多种疾病的重要武器。

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to ...